Clinical trial
An Exploratory Study to Evaluate The Efficacy And Safety of HLX10, A Humanized Monoclonal Antibody Targeting Programmed Death-1 (PD-1) Protein In Chronic Hepatitis B Patients
NCT04133259 is registered in ClinicalTrials.gov with Henlix, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Study to Evaluate The Efficacy And Safety of HLX10, A Humanized Monoclonal Antibody Targeting Programmed Death-1 (PD-1) Protein In Chronic Hepatitis B Patients
- Lead sponsor
- Henlix, Inc
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 31, 2019
- Completion date
- July 30, 2022
- Enrollment
- 44 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.